Tagista, tablets 16 mg 30 pcs

Betahistine acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS.

By direct agonist effect on H1-receptors of the inner ear vessels and indirectly through the effect on NZ-receptors it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea.

At the same time betahistine increases blood flow in the basilar artery.

It has a strong central effect being an inhibitor of NZ-receptors of the vestibular nerve nuclei.

It normalizes the conduction in neurons of the vestibular nuclei at the level of the brain stem.

Clinical manifestation of these properties is reducing the frequency and intensity of dizziness, tinnitus reduction, improvement of hearing in case of its reduction.

Pharmacokinetics

Absorbed quickly, binding with plasma proteins is low. Time to reach maximum concentration in plasma – 3 hours.

It is almost completely eliminated by kidneys in the form of metabolite (2-pyridylacetic acid) within 24 hours. The elimination half-life is 3-4 hours.

Indications

Treatment and prevention of vestibular vertigo of various origins;
Syndromes including dizziness and headache, tinnitus, progressive hearing loss, nausea and vomiting;
Meniere’s disease or syndrome.

Pharmacological effect

Betahistine acts primarily on histamine H1 and H3 receptors in the inner ear and vestibular nuclei of the central nervous system.

Through a direct agonistic effect on H1 receptors of the vessels of the inner ear, as well as indirectly through an effect on NZ receptors, it improves microcirculation and capillary permeability, normalizes endolymph pressure in the labyrinth and cochlea.

At the same time, betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of NS receptors in the nuclei of the vestibular nerve.

Normalizes conductivity in the neurons of the vestibular nuclei at the level of the brain stem.

The clinical manifestation of these properties is a decrease in the frequency and intensity of dizziness, a decrease in tinnitus, and an improvement in hearing if it is reduced.

Pharmacokinetics

Absorbed quickly, binding to plasma proteins is low. Time to reach maximum concentration in blood plasma – 3 hours

It is almost completely excreted by the kidneys in the form of a metabolite (2-pyridylacetic acid) within 24 hours. The half-life is 3-4 hours.

Special instructions

Impact on the ability to drive vehicles and operate machinery

Betahistine does not have a sedative effect and does not affect the ability to drive a car or engage in activities requiring rapid psychomotor reactions.

Active ingredient

Betahistine

Composition

1 tablet contains

Active ingredient:

Betahistine dihydrochloride 8.0 mg; 16.0 mg; 24.0 mg;

Excipients:

Microcrystalline cellulose – 54.75/109.5/164.25 mg,

Povidone (kollidon 25) – 9.0/18.0/27.0 mg

Potato starch – 20.0/40.0/60.0 mg,

Citric acid – 2.0/4.0/6.0 mg,

Colloidal silicon dioxide (aerosil), – 3.0/6.0/9.0 mg,

Talc – 2.8/5.6/8.4 mg,

Magnesium stearate – 0.45/0.9/1.35 mg.

Contraindications

Hypersensitivity to any of the components of the drug;
age under 18 years (due to lack of data);
pregnancy and lactation (due to lack of data).
With caution

Peptic ulcer of the stomach or duodenum (including a history), pheochromocytoma, bronchial asthma.

These patients should be monitored regularly during treatment.

Side Effects

Gastrointestinal disorders. the appearance of hypersensitivity reactions on the skin (rash, itching, urticaria), Quincke’s edema.

Interaction

There are no known cases of interaction or incompatibility with other drugs.

Overdose

Symptoms: nausea, vomiting, convulsions.

Treatment: gastric lavage, taking activated charcoal, symptomatic therapy.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25°C.

Keep out of the reach of children.

Shelf life

3 years

Manufacturer

Hemofarm LLC, Russia